Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   

COVID-19: Daily Top 10 Papers

  Lung Cancer

  Free Subscription

Articles published in Cancer Sci

Retrieve available abstracts of 220 articles:
HTML format

Single Articles

    July 2021
  1. SHI H, Niimi A, Takeuchi T, Shiogama K, et al
    CEBPgamma facilitates lamellipodia formation and cancer cell migration through CERS6 upregulation.
    Cancer Sci. 2021;112:2770-2780.
    PubMed     Abstract available

    June 2021
  2. FUKUDA K, Otani S, Takeuchi S, Arai S, et al
    Trametinib overcomes KRAS-G12V-induced osimertinib resistance in a leptomeningeal carcinomatosis model of EGFR-mutant lung cancer.
    Cancer Sci. 2021 Jun 19. doi: 10.1111/cas.15035.
    PubMed     Abstract available

  3. HE DH, Chen YF, Zhou YL, Zhang SB, et al
    Phytochemical library screen reveals betulinic acid as a novel Skp2-SCF E3 ligase inhibitor in non-small cell lung cancer.
    Cancer Sci. 2021 Jun 3. doi: 10.1111/cas.15005.
    PubMed     Abstract available

  4. ARIYASU R, Uchibori K, Sasaki T, Tsukahara M, et al
    Monitoring epidermal growth factor receptor C797S mutation in Japanese non-small cell lung cancer patients with serial cell-free DNA evaluation using digital droplet PCR.
    Cancer Sci. 2021;112:2371-2380.
    PubMed     Abstract available

  5. WANG H, Jiang X, Cheng Y, Ren H, et al
    MZT2A promotes NSCLC viability and invasion by increasing Akt phosphorylation via the MOZART2 domain.
    Cancer Sci. 2021;112:2210-2222.
    PubMed     Abstract available

    May 2021
  6. SHUAI S, Liao X, Wang H, Liu L, et al
    TIP30 overcomes gefitinib resistance by regulating cytoplasmic and nuclear EGFR signaling in non-small cell lung cancer.
    Cancer Sci. 2021 May 31. doi: 10.1111/cas.15000.
    PubMed     Abstract available

  7. TORIYAMA K, Takano N, Kokuba H, Kazama H, et al
    Azithromycin enhances the cytotoxicity of DNA-damaging drugs via lysosomal membrane permeabilization in lung cancer cells.
    Cancer Sci. 2021 May 29. doi: 10.1111/cas.14992.
    PubMed     Abstract available

  8. HORINOUCHI H, Nogami N, Saka H, Nishio M, et al
    Pembrolizumab Plus Pemetrexed-Platinum for Metastatic Nonsquamous Non-Small-Cell Lung Cancer: KEYNOTE-189 Japan Study.
    Cancer Sci. 2021 May 25. doi: 10.1111/cas.14980.
    PubMed     Abstract available

  9. HAN CL, Chen XR, Lan A, Hsu YL, et al
    N-glycosylated GPNMB ligand independently activates mutated EGFR signaling and promotes metastasis in NSCLC.
    Cancer Sci. 2021;112:1911-1923.
    PubMed     Abstract available

  10. LU S, Sun Z, Hu W, Yin S, et al
    PD-L1 positively regulates MET phosphorylation through inhibiting PTP1B.
    Cancer Sci. 2021;112:1878-1887.
    PubMed     Abstract available

  11. NISHIYA N, Oku Y, Ishikawa C, Fukuda T, et al
    Lamellarin 14, a derivative of marine alkaloids, inhibits the T790M/C797S mutant epidermal growth factor receptor.
    Cancer Sci. 2021;112:1963-1974.
    PubMed     Abstract available

  12. NAKAMURA IT, Ikegami M, Hasegawa N, Hayashi T, et al
    Development of an optimal protocol for molecular profiling of tumor cells in pleural effusions at single-cell level.
    Cancer Sci. 2021;112:2006-2019.
    PubMed     Abstract available

  13. WATANABE H, Ichihara E, Kayatani H, Makimoto G, et al
    VEGFR2 blockade augments the effects of tyrosine kinase inhibitors by inhibiting angiogenesis and oncogenic signaling in oncogene-driven non-small-cell lung cancers.
    Cancer Sci. 2021;112:1853-1864.
    PubMed     Abstract available

  14. SHINTANI Y, Okami J, Ito H, Ohtsuka T, et al
    Clinical features and outcomes of patients with stage I multiple primary lung cancers.
    Cancer Sci. 2021;112:1924-1935.
    PubMed     Abstract available

  15. WANG S, Cai J, Zhang S, Dong M, et al
    Loss of polarity protein Par3, via transcription factor Snail, promotes bladder cancer metastasis.
    Cancer Sci. 2021 May 1. doi: 10.1111/cas.14920.
    PubMed     Abstract available

    April 2021
  16. FUJIMOTO M, Kamiyama M, Fuse K, Ryuno H, et al
    ASK1 suppresses NK cell-mediated intravascular tumor cell clearance in lung metastasis.
    Cancer Sci. 2021;112:1633-1643.
    PubMed     Abstract available

  17. ISOMURA H, Taguchi A, Kajino T, Asai N, et al
    Conditional Ror1 knockout reveals crucial involvement in lung adenocarcinoma development and identifies novel HIF-1alpha regulator.
    Cancer Sci. 2021;112:1614-1623.
    PubMed     Abstract available

  18. SETO T, Ohashi K, Sugawara S, Nishio M, et al
    Capmatinib in Japanese patients with MET exon 14 skipping-mutated or MET-amplified advanced NSCLC: GEOMETRY mono-1 study.
    Cancer Sci. 2021;112:1556-1566.
    PubMed     Abstract available

  19. NISHIO M, Saito H, Goto K, Watanabe S, et al
    IMpower132: Atezolizumab plus platinum-based chemotherapy vs chemotherapy for advanced NSCLC in Japanese patients.
    Cancer Sci. 2021;112:1534-1544.
    PubMed     Abstract available

    March 2021
  20. KHALEDIAN B, Taguchi A, Shin-Ya K, Kondo-Ida L, et al
    Inhibition of heat shock protein 90 destabilizes receptor tyrosine kinase ROR1 in lung adenocarcinoma.
    Cancer Sci. 2021;112:1225-1234.
    PubMed     Abstract available

    February 2021
  21. LIANG ZW, Ge XX, Xu MD, Qin H, et al
    Tumor associated macrophages (TAMs) promote the metastasis and growth of non-small cell lung cancer (NSCLC) cells through NF-kappaB/PP2Ac positive feedback loop.
    Cancer Sci. 2021 Feb 20. doi: 10.1111/cas.14863.
    PubMed     Abstract available

  22. MA YC, Tian PF, Chen ZP, Yue DS, et al
    Urinary malate dehydrogenase 2 is a new biomarker for early detection of non-small cell lung cancer.
    Cancer Sci. 2021 Feb 10. doi: 10.1111/cas.14845.
    PubMed     Abstract available

  23. KOSIBATY Z, Murata Y, Minami Y, Noguchi M, et al
    ECT2 promotes lung adenocarcinoma progression through extracellular matrix dynamics and focal adhesion signaling.
    Cancer Sci. 2021;112:703-714.
    PubMed     Abstract available

    January 2021
  24. HOU Z, Wang Y, Xia N, Lv T, et al
    Pseudogene KRT17P3 drives cisplatin resistance of human NSCLC cells by modulating miR-497-5p/mTOR.
    Cancer Sci. 2021;112:275-286.
    PubMed     Abstract available

    December 2020
  25. LIU D, Zha L, Liu Y, Zhao X, et al
    beta2-AR activation promotes cleavage and nuclear translocation of Her2 and metastatic potential of cancer cells.
    Cancer Sci. 2020;111:4417-4428.
    PubMed     Abstract available

  26. TAKI T, Shiraki Y, Enomoto A, Weng L, et al
    CD109 regulates in vivo tumor invasion in lung adenocarcinoma through TGF-beta signaling.
    Cancer Sci. 2020;111:4616-4628.
    PubMed     Abstract available

  27. FUKAI K, Kojimahara N, Hoshi K, Toyota A, et al
    Combined effects of occupational exposure to hazardous operations and lifestyle-related factors on cancer incidence.
    Cancer Sci. 2020;111:4581-4593.
    PubMed     Abstract available

    November 2020
  28. SAKAI K, Tsuboi M, Kenmotsu H, Yamanaka T, et al
    Tumor mutation burden as a biomarker for lung cancer patients treated with pemetrexed and cisplatin (the JIPANG-TR).
    Cancer Sci. 2020 Nov 13. doi: 10.1111/cas.14730.
    PubMed     Abstract available

    October 2020
  29. SATA M, Sasaki S, Oikado K, Saito Y, et al
    Treatment and relapse of interstitial lung disease in nivolumab-treated patients with non-small cell lung cancer.
    Cancer Sci. 2020 Oct 30. doi: 10.1111/cas.14715.
    PubMed     Abstract available

  30. FURUYA N, Matsumoto S, Kakinuma K, Morikawa K, et al
    Feasibility of transbronchial brushing cytology specimens for next generation sequencing in peripheral lung cancer.
    Cancer Sci. 2020 Oct 30. doi: 10.1111/cas.14714.
    PubMed     Abstract available

  31. XIE W, Wang Y, Zhang Y, Xiang Y, et al
    SNP rs4142441 and MYC co-modulated lncRNA OSER1-AS1 suppresses non-small cell lung cancer by sequestering ELAVL1.
    Cancer Sci. 2020 Oct 28. doi: 10.1111/cas.14713.
    PubMed     Abstract available

  32. WAKABAYASHI Y, Masuda T, Fujitaka K, Nakashima T, et al
    Clinical significance of BIM deletion polymorphism in chemoradiotherapy for non-small cell lung cancer.
    Cancer Sci. 2020 Oct 26. doi: 10.1111/cas.14711.
    PubMed     Abstract available

  33. SAITO Y, Sasaki S, Oikado K, Tominaga J, et al
    Radiographic features and poor prognostic factors of interstitial lung disease with nivolumab for non-small cell lung cancer.
    Cancer Sci. 2020 Oct 24. doi: 10.1111/cas.14710.
    PubMed     Abstract available

  34. MIYAWAKI T, Wakuda K, Kenmotsu H, Miyawaki E, et al
    Proposing Synchronous Oligometastatic Non-Small Cell Lung Cancer Based on Progression after First-line Systemic Therapy.
    Cancer Sci. 2020 Oct 23. doi: 10.1111/cas.14707.
    PubMed     Abstract available

  35. OZAWA Y, Harutani Y, Oyanagi J, Akamatsu H, et al
    CD24, not CD47, negatively impacts upon response to PD-1/L1 inhibitors in non-small cell lung cancer with PD-L1 TPS <50.
    Cancer Sci. 2020 Oct 21. doi: 10.1111/cas.14705.
    PubMed     Abstract available

  36. GARDELLI C, Russo L, Cipolla L, Moro M, et al
    Differential glycosylation of collagen modulates lung cancer stem cell subsets through beta1 integrin-mediated interactions.
    Cancer Sci. 2020 Oct 17. doi: 10.1111/cas.14700.
    PubMed     Abstract available

  37. WANG X, Feng W, Peng C, Chen S, et al
    Targeting RNA helicase DHX33 blocks Ras-driven lung tumorigenesis in vivo.
    Cancer Sci. 2020;111:3564-3575.
    PubMed     Abstract available

  38. TONE M, Tahara S, Nojima S, Motooka D, et al
    HTR3A is correlated with unfavorable histology and promotes proliferation through ERK phosphorylation in lung adenocarcinoma.
    Cancer Sci. 2020;111:3953-3961.
    PubMed     Abstract available

  39. YANG B, Rao W, Luo H, Zhang L, et al
    Relapse-related molecular signature in early-stage lung adenocarcinomas based on base excision repair, stimulator of interferon genes pathway and tumor-infiltrating lymphocytes.
    Cancer Sci. 2020;111:3493-3502.
    PubMed     Abstract available

  40. ITO K, Murotani K, Kubo A, Kunii E, et al
    Propensity score analysis of overall survival between first- and second-generation EGFR-TKIs using real-world data.
    Cancer Sci. 2020;111:3705-3713.
    PubMed     Abstract available

  41. ZHANG X, Ruan Q, Zhai Y, Lu D, et al
    Baicalein inhibits non-small-cell lung cancer invasion and metastasis by reducing ezrin tension in inflammation microenvironment.
    Cancer Sci. 2020;111:3802-3812.
    PubMed     Abstract available

    September 2020
  42. NISHIO M, Seto T, Reck M, Garon EB, et al
    Ramucirumab or placebo plus erlotinib in EGFR-mutated, metastatic non-small-cell lung cancer: East Asian subset of RELAY.
    Cancer Sci. 2020 Sep 20. doi: 10.1111/cas.14655.
    PubMed     Abstract available

  43. SATOUCHI M, Nosaki K, Takahashi T, Nakagawa K, et al
    First-Line Pembrolizumab Versus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer: KEYNOTE-024 Japan Subset.
    Cancer Sci. 2020 Sep 14. doi: 10.1111/cas.14647.
    PubMed     Abstract available

    August 2020
  44. YANG L, Wang X, Jiao X, Tian B, et al
    Spt16 promotes lung cancer malignancy and is negatively regulated by miR-1227-5p.
    Cancer Sci. 2020 Aug 28. doi: 10.1111/cas.14627.
    PubMed     Abstract available

  45. ICHIKAWA A, Fujita Y, Hosaka Y, Kadota T, et al
    Chaperon-Mediated Autophagy Receptor Modulates Tumor Growth and Chemoresistance in Non-Small Cell Lung Cancer.
    Cancer Sci. 2020 Aug 28. doi: 10.1111/cas.14629.
    PubMed     Abstract available

  46. ICHIKI Y, Shigematsu Y, Baba T, Shiota H, et al
    Development of adoptive immunotherapy with KK-LC-1 specific TCR transduced gammadelta T cells against lung cancer cells.
    Cancer Sci. 2020 Aug 11. doi: 10.1111/cas.14612.
    PubMed     Abstract available

  47. KAGAWA Y, Furuta H, Uemura T, Watanabe N, et al
    Efficacy of local therapy for oligoprogressive disease after programmed cell death 1 blockade in advanced non-small cell lung cancer.
    Cancer Sci. 2020 Aug 7. doi: 10.1111/cas.14605.
    PubMed     Abstract available

  48. HU M, Zhao Y, Cao Y, Tang Q, et al
    DRP1 promotes lactate utilization in KRAS-mutant non-small cell lung cancer cells.
    Cancer Sci. 2020 Aug 7. doi: 10.1111/cas.14603.
    PubMed     Abstract available

  49. MIYAZATO K, Tahara H, Hayakawa Y
    Antimetastatic effects of thalidomide by inducing the functional maturation of peripheral natural killer cells.
    Cancer Sci. 2020;111:2770-2778.
    PubMed     Abstract available

  50. HORIO D, Minami T, Kitai H, Ishigaki H, et al
    Tumor-associated macrophage-derived inflammatory cytokine enhances malignant potential of malignant pleural mesothelioma.
    Cancer Sci. 2020;111:2895-2906.
    PubMed     Abstract available

  51. SHI Y, Fang N, Li Y, Guo Z, et al
    Circular RNA LPAR3 sponges microRNA-198 to facilitate esophageal cancer migration, invasion, and metastasis.
    Cancer Sci. 2020;111:2824-2836.
    PubMed     Abstract available

    July 2020
  52. NISHIYAMA A, Takeuchi S, Adachi Y, Otani S, et al
    MET amplification results in heterogeneous responses to osimertinib in EGFR-mutant lung cancer treated with erlotinib.
    Cancer Sci. 2020 Jul 31. doi: 10.1111/cas.14593.
    PubMed     Abstract available

  53. KANO H, Ichihara E, Harada D, Inoue K, et al
    Utility of immune checkpoint inhibitors in non-small-cell lung cancer patients with poor performance status.
    Cancer Sci. 2020 Jul 29. doi: 10.1111/cas.14590.
    PubMed     Abstract available

  54. CHANGCHIEN CY, Chen Y, Chang HH, Chang SY, et al
    Ability of malignant-associated pleural effusion on endothelial viability, motility, and angiogenesis in lung cancer.
    Cancer Sci. 2020 Jul 24. doi: 10.1111/cas.14584.
    PubMed     Abstract available

  55. OHGINO K, Terai H, Yasuda H, Nukaga S, et al
    Intracellular levels of reactive oxygen species correlate with ABT-263 sensitivity in non-small cell lung cancer cells.
    Cancer Sci. 2020 Jul 20. doi: 10.1111/cas.14569.
    PubMed     Abstract available

  56. SETO T, Hayashi H, Satouchi M, Goto Y, et al
    Lorlatinib in previously-treated ALK-rearranged non-small cell lung cancer: Japanese subgroup analysis of a global study.
    Cancer Sci. 2020 Jul 18. doi: 10.1111/cas.14576.
    PubMed     Abstract available

  57. KAWASAKI K, Nojima S, Hijiki S, Tahara S, et al
    FAM111B enhances proliferation of KRAS-driven lung adenocarcinoma by degrading p16.
    Cancer Sci. 2020;111:2635-2646.
    PubMed     Abstract available

  58. SATA Y, Nakajima T, Fukuyo M, Matsusaka K, et al
    High expression of CXCL14 is a biomarker of lung adenocarcinoma with micropapillary pattern.
    Cancer Sci. 2020;111:2588-2597.
    PubMed     Abstract available

    June 2020
  59. ZHONG C, Chen C, Yao F, Fang W, et al
    ZNF251 promotes the progression of lung cancer by activating ERK signaling.
    Cancer Sci. 2020 Jun 26. doi: 10.1111/cas.14547.
    PubMed     Abstract available

  60. YONESHIMA Y, Kato K, Minami H, Ikeda M, et al
    HTLV-1 seropositive patients with lung cancer treated with PD-1 inhibitors.
    Cancer Sci. 2020 Jun 18. doi: 10.1111/cas.14536.
    PubMed     Abstract available

  61. MAO R, Tan X, Xiao Y, Wang X, et al
    UCHL1 promotes expression of PD-L1 in non-small cell lung cancer cells.
    Cancer Sci. 2020 Jun 15. doi: 10.1111/cas.14529.
    PubMed     Abstract available

  62. DENG M, Liu B, Zhang Z, Chen Y, et al
    The knockdown of GPSM2 promotes the metastasis of non-small cell lung cancer by inducing the expression of Snail.
    Cancer Sci. 2020 Jun 10. doi: 10.1111/cas.14519.
    PubMed     Abstract available

  63. WU ZX, Yang Y, Wang G, Wang JQ, et al
    Dual TTK/CLK2 inhibitor, CC-671, selectively antagonizes ABCG2-mediated multidrug resistance in lung cancer cells.
    Cancer Sci. 2020 Jun 1. doi: 10.1111/cas.14505.
    PubMed     Abstract available

  64. OKAZAKI Y, Chew SH, Nagai H, Yamashita Y, et al
    Overexpression of miR-199/214 is a distinctive feature of iron-induced and asbestos-induced sarcomatoid mesothelioma in rats.
    Cancer Sci. 2020;111:2016-2027.
    PubMed     Abstract available

  65. MATSUBARA D, Yoshimoto T, Soda M, Amano Y, et al
    Reciprocal expression of trefoil factor-1 and thyroid transcription factor-1 in lung adenocarcinomas.
    Cancer Sci. 2020;111:2183-2195.
    PubMed     Abstract available

  66. DU P, Hu T, An Z, Li P, et al
    In vitro and in vivo synergistic efficacy of ceritinib combined with programmed cell death ligand-1 inhibitor in anaplastic lymphoma kinase-rearranged non-small-cell lung cancer.
    Cancer Sci. 2020;111:1887-1898.
    PubMed     Abstract available

  67. HUANG J, Li J, Zheng S, Lu Z, et al
    Tumor microenvironment characterization identifies two lung adenocarcinoma subtypes with specific immune and metabolic state.
    Cancer Sci. 2020;111:1876-1886.
    PubMed     Abstract available

    May 2020
  68. NGUYEN PA, Chang CC, Galvin CJ, Wang YC, et al
    Statins use and its impact in EGFR-TKIs resistance to prolong the survival of lung cancer patients: A Cancer Registry Cohort Study in Taiwan.
    Cancer Sci. 2020 May 22. doi: 10.1111/cas.14493.
    PubMed     Abstract available

  69. OTSUBO K, Iwama E, Ijichi K, Kubo N, et al
    Paired genetic analysis by next-generation sequencing of lung cancer and associated idiopathic pulmonary fibrosis.
    Cancer Sci. 2020 May 19. doi: 10.1111/cas.14488.
    PubMed     Abstract available

  70. UDAGAWA H, Kirita K, Naito T, Nomura S, et al
    Feasibility and utility of transbronchial cryobiopsy in precision medicine for lung cancer: prospective single-arm study.
    Cancer Sci. 2020 May 19. doi: 10.1111/cas.14489.
    PubMed     Abstract available

  71. AKAZAWA Y, Saito Y, Yoshikawa T, Saito K, et al
    Efficacy of immunotherapy targeting the neoantigen derived from EGFR T790M/C797S mutation in non-small cell lung cancer.
    Cancer Sci. 2020 May 11. doi: 10.1111/cas.14451.
    PubMed     Abstract available

  72. FUKUDA K, Takeuchi S, Arai S, Kita K, et al
    GSK-3 inhibition overcomes EMT-associated resistance to osimertinib in EGFR mutant lung cancer.
    Cancer Sci. 2020 May 11. doi: 10.1111/cas.14454.
    PubMed     Abstract available

  73. SUN N, Sun S, Gao Y, Li Y, et al
    Utility of isocitrate dehydrogenase 1 as a serum protein biomarker for the early detection of non-small-cell lung cancer: A multicenter in vitro diagnostic clinical trial.
    Cancer Sci. 2020;111:1739-1749.
    PubMed     Abstract available

    April 2020
  74. KANDA S, Ohe Y, Goto Y, Horinouchi H, et al
    Five-year safety and efficacy data from a phase Ib study of nivolumab and chemotherapy in advanced non-small-cell lung cancer.
    Cancer Sci. 2020 Apr 11. doi: 10.1111/cas.14410.
    PubMed     Abstract available

  75. OKAZAKI Y, Misawa N, Akatsuka S, Kohyama N, et al
    Frequent homozygous deletion of Cdkn2a/2b in tremolite-induced malignant mesothelioma in rats.
    Cancer Sci. 2020;111:1180-1192.
    PubMed     Abstract available

  76. LIU D, Xing S, Wang W, Huang X, et al
    Prognostic value of serum soluble interleukin-23 receptor and related T-helper 17 cell cytokines in non-small cell lung carcinoma.
    Cancer Sci. 2020;111:1093-1102.
    PubMed     Abstract available

    March 2020
  77. OKIMOTO T, Kotani H, Iida Y, Koyanagi A, et al
    Pemetrexed sensitizes human lung cancer cells to cytotoxic immune cells.
    Cancer Sci. 2020 Mar 31. doi: 10.1111/cas.14401.
    PubMed     Abstract available

  78. NISHIO M, Kato T, Niho S, Yamamoto N, et al
    Safety and efficacy of first-line dacomitinib in Japanese patients with advanced non-small cell lung cancer.
    Cancer Sci. 2020 Mar 11. doi: 10.1111/cas.14384.
    PubMed     Abstract available

  79. LEE KY, Sheung PW, Chou CM, Lin BX, et al
    Elevation of CD109 promotes metastasis and drug resistance in lung cancer via activation of EGFR-AKT-mTOR signaling.
    Cancer Sci. 2020 Mar 4. doi: 10.1111/cas.14373.
    PubMed     Abstract available

  80. YANAGITANI N, Uchibori K, Koike S, Tsukahara M, et al
    Drug resistance mechanisms in Japanese anaplastic lymphoma kinase-positive non-small cell lung cancer and the clinical responses based on the resistant mechanisms.
    Cancer Sci. 2020;111:932-939.
    PubMed     Abstract available

  81. KIMURA K, Matsumoto S, Harada T, Morii E, et al
    ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target.
    Cancer Sci. 2020;111:951-961.
    PubMed     Abstract available

  82. TAKEDA T, Yamamoto H, Suzawa K, Tomida S, et al
    YES1 activation induces acquired resistance to neratinib in HER2-amplified breast and lung cancers.
    Cancer Sci. 2020;111:849-856.
    PubMed     Abstract available

    February 2020
  83. WANG W, Zhuang R, Ma H, Fang L, et al
    The diagnostic value of a 7-autoantibody panel and a nomogram for predicting the risk of non-small cell lung cancer.
    Cancer Sci. 2020 Feb 28. doi: 10.1111/cas.14371.
    PubMed     Abstract available

  84. SEKINE I, Shintani Y, Shukuya T, Takayama K, et al
    A Japanese lung cancer registry study on demographics and treatment modalities in medically treated patients.
    Cancer Sci. 2020 Feb 26. doi: 10.1111/cas.14368.
    PubMed     Abstract available

  85. YE L, Jia K, Wang L, Li W, et al
    CD137, an attractive candidate for the immunotherapy of lung cancer.
    Cancer Sci. 2020 Feb 19. doi: 10.1111/cas.14354.
    PubMed     Abstract available

  86. OSUMI H, Horiguchi H, Kadomatsu T, Tashiro K, et al
    Tumor cell-derived ANGPTL2 establishes a preference for glycolytic metabolism in lung cancer cells.
    Cancer Sci. 2020 Feb 3. doi: 10.1111/cas.14337.
    PubMed     Abstract available

  87. SHIMADA Y, Kudo Y, Maehara S, Matsubayashi J, et al
    Ubiquitin C-terminal hydrolase-L1 has prognostic relevance and is a therapeutic target for high-grade neuroendocrine lung cancers.
    Cancer Sci. 2020;111:610-620.
    PubMed     Abstract available

  88. SHIMA T, Shimoda M, Shigenobu T, Ohtsuka T, et al
    Infiltration of tumor-associated macrophages is involved in tumor programmed death-ligand 1 expression in early lung adenocarcinoma.
    Cancer Sci. 2020;111:727-738.
    PubMed     Abstract available

  89. ZHANG S, Li G, Liu C, Lu S, et al
    miR-30e-5p represses angiogenesis and metastasis by directly targeting AEG-1 in squamous cell carcinoma of the head and neck.
    Cancer Sci. 2020;111:356-368.
    PubMed     Abstract available

  90. ZHANG Y, Du H, Li Y, Yuan Y, et al
    Elevated TRIM23 expression predicts cisplatin resistance in lung adenocarcinoma.
    Cancer Sci. 2020;111:637-646.
    PubMed     Abstract available

    January 2020
  91. SUGIMORI M, Sugimori K, Tsuchiya H, Suzuki Y, et al
    Quantitative monitoring of circulating tumor DNA in patients with advanced pancreatic cancer undergoing chemotherapy.
    Cancer Sci. 2020;111:266-278.
    PubMed     Abstract available

  92. HUANG T, Zhou X, Mao X, Yu C, et al
    Lactate-fueled oxidative metabolism drives DNA methyltransferase 1-mediated transcriptional co-activator with PDZ binding domain protein activation.
    Cancer Sci. 2020;111:186-199.
    PubMed     Abstract available

    December 2019
  93. SAIGUSA D, Motoike IN, Saito S, Zorzi M, et al
    Impacts of NRF2 Activation in Non-Small-Cell Lung Cancer Cell Lines on Extracellular Metabolites.
    Cancer Sci. 2019 Dec 11. doi: 10.1111/cas.14278.
    PubMed     Abstract available

  94. LEI L, Wang WX, Zhu YC, Li JL, et al
    The potential mechanism of primary resistance to icotinib in EGFR uncommon mutant advanced non-small cell lung cancer: a multi-center study.
    Cancer Sci. 2019 Dec 11. doi: 10.1111/cas.14277.
    PubMed     Abstract available

    November 2019
  95. TAKEUCHI S, Hase T, Shimizu S, Ando M, et al
    Phase I study of vorinostat with gefitinib in BIM deletion polymorphism/EGFR mutation double-positive lung cancer.
    Cancer Sci. 2019 Nov 29. doi: 10.1111/cas.14260.
    PubMed     Abstract available

  96. ANDO T, Kage H, Matsumoto Y, Zokumasu K, et al
    Integrin alpha11 in Non-Small Cell Lung Cancer is Associated with Tumor Progression and Postoperative Recurrence.
    Cancer Sci. 2019 Nov 28. doi: 10.1111/cas.14257.
    PubMed     Abstract available

  97. KONG L, Cai FY, Yao XM, Jing M, et al
    RPV-modified Epirubicin and dioscin co-delivery liposomes suppress non-small cell lung cancer growth by limiting nutrition supply.
    Cancer Sci. 2019 Nov 28. doi: 10.1111/cas.14256.
    PubMed     Abstract available

  98. KAMATA T, Yoshida S, Takami M, Ihara F, et al
    Immunological Features of a Lung Cancer Patient Achieving an Objective Response with Anti-PD-1 Blockade Therapy.
    Cancer Sci. 2019 Nov 2. doi: 10.1111/cas.14222.
    PubMed     Abstract available

  99. SAKAMOTO S, Inoue H, Kaneko MK, Ogasawara S, et al
    Generation and evaluation of a chimeric antibody against coxsackievirus and adenovirus receptor for cancer therapy.
    Cancer Sci. 2019;110:3595-3602.
    PubMed     Abstract available

  100. TONG M, Gao M, Xu Y, Fu L, et al
    SHR-A1403, a novel c-mesenchymal-epithelial transition factor (c-Met) antibody-drug conjugate, overcomes AZD9291 resistance in non-small cell lung cancer cells overexpressing c-Met.
    Cancer Sci. 2019;110:3584-3594.
    PubMed     Abstract available

    October 2019
  101. KENMOTSU H, Yoh K, Mori K, Ono A, et al
    Phase II study of nab-paclitaxel+carboplatin for patients with non-small-cell lung cancer and interstitial lung disease.
    Cancer Sci. 2019 Oct 13. doi: 10.1111/cas.14217.
    PubMed     Abstract available

  102. GONG R, Lin W, Gao A, Liu Y, et al
    Forkhead box C1 promotes metastasis and invasion of non-small cell lung cancer by binding directly to the lysyl oxidase promoter.
    Cancer Sci. 2019 Oct 9. doi: 10.1111/cas.14213.
    PubMed     Abstract available

  103. FENG S, Wang H, Wang Y, Sun R, et al
    Apatinib induces 3-hydroxybutyric acid production in the liver of mice by peroxisome proliferator-activated receptor alpha activation to aid its antitumor effect.
    Cancer Sci. 2019;110:3328-3339.
    PubMed     Abstract available

    September 2019
  104. KHANDELWAL A, Seam RK, Gupta M, Rana MK, et al
    Circulating microRNA-590-5p acts as a liquid biopsy marker in non-small cell lung cancer.
    Cancer Sci. 2019 Sep 14. doi: 10.1111/cas.14199.
    PubMed     Abstract available

  105. MAKINO Y, Makihara-Ando R, Ogawa T, Sato H, et al
    Individual optimal dose of amrubicin to prevent severe neutropenia in Japanese patients with lung cancer.
    Cancer Sci. 2019 Sep 10. doi: 10.1111/cas.14194.
    PubMed     Abstract available

  106. WANG L, Liang Y, Mao Q, Xia W, et al
    Circular RNA circCRIM1 inhibits invasion and metastasis in lung adenocarcinoma through the microRNA (miR)-182/miR-93-leukemia inhibitory factor receptor pathway.
    Cancer Sci. 2019;110:2960-2972.
    PubMed     Abstract available

  107. YOSHIMOTO T, Matsubara D, Soda M, Ueno T, et al
    Mucin 21 is a key molecule involved in the incohesive growth pattern in lung adenocarcinoma.
    Cancer Sci. 2019;110:3006-3011.
    PubMed     Abstract available

  108. SHINCHI Y, Komohara Y, Yonemitsu K, Sato K, et al
    Accurate expression of PD-L1/L2 in lung adenocarcinoma cells: A retrospective study by double immunohistochemistry.
    Cancer Sci. 2019;110:2711-2721.
    PubMed     Abstract available

    August 2019
  109. MENG MB, Wang HH, Zaorsky NG, Sun BS, et al
    Risk-adapted stereotactic body radiation therapy for central and ultra-central early-stage inoperable non-small cell lung cancer.
    Cancer Sci. 2019 Aug 28. doi: 10.1111/cas.14185.
    PubMed     Abstract available

  110. ZHOU X, Shou J, Sheng J, Xu C, et al
    Molecular and clinical analysis of Chinese patients with ALK-rearranged non-small cell lung cancer.
    Cancer Sci. 2019 Aug 23. doi: 10.1111/cas.14177.
    PubMed     Abstract available

  111. YAMASUGE W, Yamamoto Y, Fujigaki H, Hoshi M, et al
    Ido2 depletion suppresses tumor growth in a mouse model of Lewis lung carcinoma.
    Cancer Sci. 2019 Aug 23. doi: 10.1111/cas.14179.
    PubMed     Abstract available

  112. KITA K, Fukuda K, Takahashi H, Tanimoto A, et al
    Patient-derived xenograft models of non-small cell lung cancer for evaluating targeted drug sensitivity and resistance.
    Cancer Sci. 2019 Aug 20. doi: 10.1111/cas.14171.
    PubMed     Abstract available

  113. MATSUMOTO Y, Sawa K, Fukui M, Oyanagi J, et al
    Impact of tumor microenvironment on the efficacy of EGFR-TKIs in patients with EGFR-mutant non-small cell lung cancer.
    Cancer Sci. 2019 Aug 1. doi: 10.1111/cas.14156.
    PubMed     Abstract available

  114. NUMANO T, Higuchi H, Alexander DB, Alexander WT, et al
    MWCNT-7 administered to the lung by intratracheal instillation induces development of pleural mesothelioma in F344 rats.
    Cancer Sci. 2019;110:2485-2492.
    PubMed     Abstract available

  115. KOTANI N, Yamaguchi A, Ohnishi T, Kuwahara R, et al
    Proximity proteomics identifies cancer cell membrane cis-molecular complex as a potential cancer target.
    Cancer Sci. 2019;110:2607-2619.
    PubMed     Abstract available

  116. KAGE H, Kohsaka S, Shinozaki-Ushiku A, Hiraishi Y, et al
    Small lung tumor biopsy samples are feasible for high quality targeted next generation sequencing.
    Cancer Sci. 2019;110:2652-2657.
    PubMed     Abstract available

  117. KIM Y, Shiba-Ishii A, Ramirez K, Muratani M, et al
    Carcinogen-induced tumors in SFN-transgenic mice harbor a characteristic mutation spectrum of human lung adenocarcinoma.
    Cancer Sci. 2019;110:2431-2441.
    PubMed     Abstract available

    July 2019
  118. KITAZONO S, Sakai K, Yanagitani N, Ariyasu R, et al
    Barcode sequencing identifies resistant mechanisms to EGFR-inhibitors in circulating tumor DNA of lung cancer patients.
    Cancer Sci. 2019 Jul 30. doi: 10.1111/cas.14153.
    PubMed     Abstract available

  119. MIAO W, Sakai K, Sato H, Imamura R, et al
    Impaired ligand-dependent MET activation caused by an extracellularSEMA domain missense mutation in lung cancer.
    Cancer Sci. 2019 Jul 24. doi: 10.1111/cas.14142.
    PubMed     Abstract available

  120. WU Y, Jamal M, Xie T, Sun J, et al
    Uridine-cytidine kinase 2 (UCK2): A potential diagnostic and prognostic biomarker for lung cancer.
    Cancer Sci. 2019 Jul 6. doi: 10.1111/cas.14125.
    PubMed     Abstract available

  121. HIRASHIMA T, Satouchi M, Hida T, Nishio M, et al
    Osimertinib for Japanese Patients with T790M-positive Advanced Non-Small Cell Lung Cancer: A Pooled Subgroup Analysis.
    Cancer Sci. 2019 Jul 2. doi: 10.1111/cas.14120.
    PubMed     Abstract available

  122. ITO T, Nakamura A, Tanaka I, Tsuboi Y, et al
    CADM1 associates with Hippo pathway core kinases; membranous co-expression of CADM1 and LATS2 in lung tumors predicts good prognosis.
    Cancer Sci. 2019;110:2284-2295.
    PubMed     Abstract available

  123. FAN CM, Wang JP, Tang YY, Zhao J, et al
    circMAN1A2 could serve as a novel serum biomarker for malignant tumors.
    Cancer Sci. 2019;110:2180-2188.
    PubMed     Abstract available

    June 2019
  124. CHEN H, Chong W, Teng C, Yao Y, et al
    The Immune Response-related Mutational Signatures and Driver Genes in Non-small Cell Lung Cancer.
    Cancer Sci. 2019 Jun 21. doi: 10.1111/cas.14113.
    PubMed     Abstract available

  125. LIANG W, Guo M, Pan Z, Cai X, et al
    Association between certain non-small cell lung cancer driver mutations and predictive markers for chemotherapy or programmed death-ligand 1 inhibition.
    Cancer Sci. 2019;110:2014-2021.
    PubMed     Abstract available

  126. LI X, Zhu J, Liu Y, Duan C, et al
    MicroRNA-331-3p inhibits epithelial-mesenchymal transition by targeting ErbB2 and VAV2 through the Rac1/PAK1/beta-catenin axis in non-small-cell lung cancer.
    Cancer Sci. 2019;110:1883-1896.
    PubMed     Abstract available

    May 2019
  127. SONG L, Ma S, Chen L, Miao L, et al
    The long-term prognostic significance of IL-17 producing T cells in patients with non-small cell lung cancer.
    Cancer Sci. 2019 May 17. doi: 10.1111/cas.14068.
    PubMed     Abstract available

  128. YU S, Yang D, Ye Y, Liu P, et al
    lncRNA AFAP1-AS1 promotes malignant phenotype through binding with LSD1 and repressing HBP1 in non-small cell lung cancer.
    Cancer Sci. 2019 May 8. doi: 10.1111/cas.14039.
    PubMed     Abstract available

  129. HINO O, Abe M, Han B, Yan Y, et al
    In commemoration of the 2018 Mataro Nagayo Prize: A road to early diagnosis and monitoring of asbestos-related mesothelioma.
    Cancer Sci. 2019;110:1518-1524.
    PubMed     Abstract available

  130. TU W, Yang B, Leng X, Pei X, et al
    Testis-specific protein, Y-linked 1 activates PI3K/AKT and RAS signaling pathways through suppressing IGFBP3 expression during tumor progression.
    Cancer Sci. 2019;110:1573-1586.
    PubMed     Abstract available

  131. SUDO H, Tsuji AB, Sugyo A, Saga T, et al
    Therapeutic efficacy evaluation of radioimmunotherapy with (90) Y-labeled anti-podoplanin antibody NZ-12 for mesothelioma.
    Cancer Sci. 2019;110:1653-1664.
    PubMed     Abstract available

    April 2019
  132. ANDO A, Hashimoto N, Sakamoto K, Omote N, et al
    Repressive role of stabilized HIF1alpha expression on TGFbeta-induced extracellular matrix production in lung cancer cells.
    Cancer Sci. 2019 Apr 20. doi: 10.1111/cas.14027.
    PubMed     Abstract available

  133. SAKAI K, Ohira T, Matsubayashi J, Yoneshige A, et al
    Performance of Oncomine Fusion Transcript kit for formalin-fixed, paraffin-embedded lung cancer specimens.
    Cancer Sci. 2019 Apr 10. doi: 10.1111/cas.14016.
    PubMed     Abstract available

  134. MASUDA N, Ohe Y, Gemma A, Kusumoto M, et al
    Safety and effectiveness of alectinib in a real-world surveillance study in patients with ALK-positive non-small-cell lung cancer in Japan.
    Cancer Sci. 2019;110:1401-1407.
    PubMed     Abstract available

    March 2019
  135. FURUTA M, Kikuchi H, Shoji T, Takashima Y, et al
    DLL3 regulates the migration and invasion of small cell lung cancer by modulating Snail.
    Cancer Sci. 2019 Mar 15. doi: 10.1111/cas.13997.
    PubMed     Abstract available

  136. WANG L, Li X, Ren Y, Geng H, et al
    Cancer-associated fibroblasts contribute to cisplatin resistance via modulating ANXA3 in lung cancer cells.
    Cancer Sci. 2019 Mar 13. doi: 10.1111/cas.13998.
    PubMed     Abstract available

  137. GUO R, Li Y, Wang Z, Bai H, et al
    HIF-1alpha and NF-kappaB play important roles in regulating PD-L1 expression by EGFR mutants in non-small cell lung cancer cells.
    Cancer Sci. 2019 Mar 7. doi: 10.1111/cas.13989.
    PubMed     Abstract available

  138. IEGUCHI K, Maru Y
    Roles of EphA1/A2 and ephrin-A1 in cancer.
    Cancer Sci. 2019;110:841-848.
    PubMed     Abstract available

  139. NISHIO M, Takahashi T, Yoshioka H, Nakagawa K, et al
    KEYNOTE-025: Phase 1b study of pembrolizumab in Japanese patients with previously treated programmed death ligand 1-positive advanced non-small-cell lung cancer.
    Cancer Sci. 2019;110:1012-1020.
    PubMed     Abstract available

  140. ZHA L, Kitamura Y, Kitamura T, Liu R, et al
    Population-based cohort study on health effects of asbestos exposure in Japan.
    Cancer Sci. 2019;110:1076-1084.
    PubMed     Abstract available

  141. MIYAUCHI E, Matsuda T, Kiyotani K, Low SK, et al
    Significant differences in T cell receptor repertoires in lung adenocarcinomas with and without epidermal growth factor receptor mutations.
    Cancer Sci. 2019;110:867-874.
    PubMed     Abstract available

    February 2019
  142. SUKHBAATAR A, Mori S, Saiki Y, Takahashi T, et al
    Lymph node resection induces the activation of tumor cells in the lungs.
    Cancer Sci. 2019;110:509-518.
    PubMed     Abstract available

  143. YONEDA K, Kuwata T, Chikaishi Y, Mori M, et al
    Detection of circulating tumor cells with a novel microfluidic system in malignant pleural mesothelioma.
    Cancer Sci. 2019;110:726-733.
    PubMed     Abstract available

    January 2019
  144. WAHIDUZZAMAN M, Karnan S, Ota A, Hanamura I, et al
    Establishment and characterization of CRISPR/Cas9-mediated NF2(-/-) human mesothelial cell line: Molecular insight into fibroblast growth factor receptor 2 in malignant pleural mesothelioma.
    Cancer Sci. 2019;110:180-193.
    PubMed     Abstract available

  145. UCHIDA A, Seki N, Mizuno K, Misono S, et al
    Involvement of dual-strand of the miR-144 duplex and their targets in the pathogenesis of lung squamous cell carcinoma.
    Cancer Sci. 2019;110:420-432.
    PubMed     Abstract available

    December 2018
  146. PAN H, Peng Z, Lin J, Ren X, et al
    Forkhead box C1 boosts triple-negative breast cancer metastasis through activating the transcription of chemokine receptor-4.
    Cancer Sci. 2018;109:3794-3804.
    PubMed     Abstract available

  147. LIAO M, Liu Q, Li B, Liao W, et al
    A group of long noncoding RNAs identified by data mining can predict the prognosis of lung adenocarcinoma.
    Cancer Sci. 2018;109:4033-4044.
    PubMed     Abstract available

  148. IWAMA E, Sakai K, Azuma K, Harada D, et al
    Exploration of resistance mechanisms for epidermal growth factor receptor-tyrosine kinase inhibitors based on plasma analysis by digital polymerase chain reaction and next-generation sequencing.
    Cancer Sci. 2018;109:3921-3933.
    PubMed     Abstract available

  149. GU MM, Gao D, Yao PA, Yu L, et al
    p53-inducible gene 3 promotes cell migration and invasion by activating the FAK/Src pathway in lung adenocarcinoma.
    Cancer Sci. 2018;109:3783-3793.
    PubMed     Abstract available

    November 2018
  150. HAYASHI K, Yamamoto N, Nakajima M, Nomoto A, et al
    Clinical Outcomes of Carbon-Ion Radiotherapy for Locally Advanced Non-Small-Cell Lung Cancer.
    Cancer Sci. 2018 Nov 22. doi: 10.1111/cas.13890.
    PubMed     Abstract available

  151. NIU L, Song X, Wang N, Xue L, et al
    Tumor-derived exosomal proteins as diagnostic biomarkers in non-small cell lung cancer.
    Cancer Sci. 2018 Nov 8. doi: 10.1111/cas.13862.
    PubMed     Abstract available

  152. WATANABE S, Hayashi H, Haratani K, Shimizu S, et al
    Mutational activation of the EGFR down-regulates MHC class I expression via the ERK in non-small cell lung cancer.
    Cancer Sci. 2018 Nov 3. doi: 10.1111/cas.13860.
    PubMed     Abstract available

  153. KIMURA S, Tanaka K, Harada T, Liu R, et al
    Sensitivity of epidermal growth factor receptor with single or double uncommon mutations to afatinib confirmed by a visual assay.
    Cancer Sci. 2018;109:3657-3661.
    PubMed     Abstract available

  154. TAKAHASHI Y, Shien K, Tomida S, Oda S, et al
    Comparative mutational evaluation of multiple lung cancers by multiplex oncogene mutation analysis.
    Cancer Sci. 2018;109:3634-3642.
    PubMed     Abstract available

  155. KIM IG, Lee JH, Kim SY, Hwang HM, et al
    Hypoxia-inducible transgelin 2 selects epithelial-to-mesenchymal transition and gamma-radiation-resistant subtypes by focal adhesion kinase-associated insulin-like growth factor 1 receptor activation in non-small-cell lung cancer cells.
    Cancer Sci. 2018;109:3519-3531.
    PubMed     Abstract available

    October 2018
  156. QIU L, Yu Q, Zhou Y, Zheng S, et al
    Functionally impaired Tfh cells induce regulatory B cells and CD14(+) HLA-DR(-) cells differentiation in non-small cell lung cancer.
    Cancer Sci. 2018 Oct 16. doi: 10.1111/cas.13836.
    PubMed     Abstract available

  157. HONG MJ, Yoo SS, Choi JE, Kang HG, et al
    A functional intronic variant of SLC5A10 affects DRG2 expression and survival outcomes of early-stage non-small cell lung cancer.
    Cancer Sci. 2018 Oct 3. doi: 10.1111/cas.13814.
    PubMed     Abstract available

  158. ZHAO X, Li X, Zhou L, Ni J, et al
    LncRNA HOXA11-AS drives cisplatin resistance of human LUAD cells via modulating miR-454-3p/Stat3.
    Cancer Sci. 2018;109:3068-3079.
    PubMed     Abstract available

  159. KATO Y, Ninomiya K, Ohashi K, Tomida S, et al
    Combined effect of cabozantinib and gefitinib in crizotinib-resistant lung tumors harboring ROS1 fusions.
    Cancer Sci. 2018;109:3149-3158.
    PubMed     Abstract available

  160. LIU M, Jiang L, Fu X, Wang W, et al
    Cytoplasmic liver kinase B1 promotes the growth of human lung adenocarcinoma by enhancing autophagy.
    Cancer Sci. 2018;109:3055-3067.
    PubMed     Abstract available

  161. MAEMURA K, Watanabe K, Ando T, Hiyama N, et al
    Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma.
    Cancer Sci. 2018;109:3326-3335.
    PubMed     Abstract available

    September 2018
  162. ZHAO Y, Shao Q, Zhu H, Xu H, et al
    Resveratrol ameliorates Lewis lung carcinoma-bearing mice development, decreases granulocytic myeloid-derived suppressor cell accumulation and impairs its suppressive ability.
    Cancer Sci. 2018;109:2677-2686.
    PubMed     Abstract available

  163. HIDA T, Seto T, Horinouchi H, Maemondo M, et al
    Phase II study of ceritinib in alectinib-pretreated patients with anaplastic lymphoma kinase-rearranged metastatic non-small-cell lung cancer in Japan: ASCEND-9.
    Cancer Sci. 2018;109:2863-2872.
    PubMed     Abstract available

  164. YAMAMOTO Y, Miyazato K, Takahashi K, Yoshimura N, et al
    Lung-resident natural killer cells control pulmonary tumor growth in mice.
    Cancer Sci. 2018;109:2670-2676.
    PubMed     Abstract available

  165. PONGSUCHART M, Kuchimaru T, Yonezawa S, Tran DTP, et al
    Novel lymphoid enhancer-binding factor 1-cytoglobin axis promotes extravasation of osteosarcoma cells into the lungs.
    Cancer Sci. 2018;109:2746-2756.
    PubMed     Abstract available

    August 2018
  166. XU S, Lam SK, Cheng PN, Ho JC, et al
    Recombinant human arginase induces apoptosis via oxidative stress and cell cycle arrest in small cell lung cancer.
    Cancer Sci. 2018 Aug 28. doi: 10.1111/cas.13782.
    PubMed     Abstract available

  167. LIU YP, Chen CH, Yen CH, Tung CW, et al
    HIV Tat-TIP30 interaction promotes metastasis by enhancing the nuclear translocation of Snail in lung cancer cell lines.
    Cancer Sci. 2018 Aug 12. doi: 10.1111/cas.13768.
    PubMed     Abstract available

  168. SATO H, Yamamoto H, Sakaguchi M, Shien K, et al
    Combined inhibition of MEK and PI3K pathways overcomes acquired resistance to EGFR-TKIs in non-small cell lung cancer.
    Cancer Sci. 2018 Aug 10. doi: 10.1111/cas.13763.
    PubMed     Abstract available

  169. GONG WJ, Liu JY, Yin JY, Cui JJ, et al
    Resistin facilitates metastasis of lung adenocarcinoma through the TLR4/Src/EGFR/PI3K/NF-kappaB pathway.
    Cancer Sci. 2018;109:2391-2400.
    PubMed     Abstract available

  170. ZHU Y, Tang L, Zhao S, Sun B, et al
    CXCR4-mediated osteosarcoma growth and pulmonary metastasis is suppressed by MicroRNA-613.
    Cancer Sci. 2018;109:2412-2422.
    PubMed     Abstract available

    July 2018
  171. LIU M, Zhang H, Li Y, Wang R, et al
    HOTAIR, a long non-coding RNA, is a marker of abnormal cell cycle regulation in lung cancer.
    Cancer Sci. 2018 Jul 26. doi: 10.1111/cas.13745.
    PubMed     Abstract available

  172. MURAKAMI H, Nokihara H, Hayashi H, Seto T, et al
    Clinical activity of ASP8273 in Asian patients with non-small cell lung cancer with EGFR activating and T790M mutations.
    Cancer Sci. 2018 Jul 4. doi: 10.1111/cas.13724.
    PubMed     Abstract available

  173. KAWASAKI N, Miwa T, Hokari S, Sakurai T, et al
    Long noncoding RNA NORAD regulates transforming growth factor-beta signaling and epithelial-to-mesenchymal transition-like phenotype.
    Cancer Sci. 2018;109:2211-2220.
    PubMed     Abstract available

    June 2018
  174. WATANABE M, Kenmotsu H, Ko R, Wakuda K, et al
    Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter.
    Cancer Sci. 2018 Jun 14. doi: 10.1111/cas.13692.
    PubMed     Abstract available

  175. QIN T, Huang D, Liu Z, Zhang X, et al
    TNFSF15 promotes lymphatic metastasis via up-regulation of VEGFC in a mouse model of lung cancer.
    Cancer Sci. 2018 Jun 11. doi: 10.1111/cas.13665.
    PubMed     Abstract available

  176. WANG H, Zhang G
    Endoplasmic reticulum stress-mediated autophagy protects against beta,beta-dimethylacrylshikonin-induced apoptosis in lung adenocarcinoma cells.
    Cancer Sci. 2018;109:1889-1901.
    PubMed     Abstract available

  177. ALAEE M, Nool K, Pasdar M
    Plakoglobin restores tumor suppressor activity of p53(R175H) mutant by sequestering the oncogenic potential of beta-catenin.
    Cancer Sci. 2018;109:1876-1888.
    PubMed     Abstract available

  178. FENG W, Xie Q, Liu S, Ji Y, et al
    Kruppel-like factor 4 promotes c-Met amplification-mediated gefitinib resistance in non-small-cell lung cancer.
    Cancer Sci. 2018;109:1775-1786.
    PubMed     Abstract available

    May 2018
  179. AZUMA K, Nishio M, Hayashi H, Kiura K, et al
    ASP8273 tolerability and antitumor activity in TKI-naive Japanese patients with EGFR mutation-positive non-small cell lung cancer.
    Cancer Sci. 2018 May 28. doi: 10.1111/cas.13651.
    PubMed     Abstract available

  180. LI S, Ma F, Jiang K, Shan H, et al
    Long non-coding RNA metastasis-associated lung adenocarcinoma transcript 1 promotes lung adenocarcinoma by directly interacting with specificity protein 1.
    Cancer Sci. 2018;109:1346-1356.
    PubMed     Abstract available

  181. LIU K, Gao H, Wang Q, Wang L, et al
    Hispidulin suppresses cell growth and metastasis by targeting PIM1 through JAK2/STAT3 signaling in colorectal cancer.
    Cancer Sci. 2018;109:1369-1381.
    PubMed     Abstract available

  182. SEMBA T, Sugihara E, Kamoshita N, Ueno S, et al
    Periostin antisense oligonucleotide suppresses bleomycin-induced formation of a lung premetastatic niche for melanoma.
    Cancer Sci. 2018;109:1447-1454.
    PubMed     Abstract available

  183. HAYASHI K, Yamamoto N, Karube M, Nakajima M, et al
    Feasibility of carbon-ion radiotherapy for re-irradiation of locoregionally recurrent, metastatic, or secondary lung tumors.
    Cancer Sci. 2018;109:1562-1569.
    PubMed     Abstract available

    April 2018
  184. AKAMATSU H, Katakami N, Okamoto I, Kato T, et al
    Osimertinib in Japanese patients with EGFR T790M mutation-positive advanced non-small cell lung cancer: AURA3 trial.
    Cancer Sci. 2018 Apr 26. doi: 10.1111/cas.13623.
    PubMed     Abstract available

  185. WANG Y, Lei L, Zheng YW, Zhang L, et al
    Odd-skipped related 1 inhibits lung cancer proliferation and invasion by reducing Wnt signaling through the suppression of SOX9 and beta-catenin.
    Cancer Sci. 2018 Apr 16. doi: 10.1111/cas.13614.
    PubMed     Abstract available

  186. TANAKA I, Sato M, Kato T, Goto D, et al
    eIF2beta, a Subunit of Translation-Initiation Factor EIF2, Is a Potential Therapeutic Target for Non-Small Cell Lung Cancer.
    Cancer Sci. 2018 Apr 6. doi: 10.1111/cas.13602.
    PubMed     Abstract available

    March 2018
  187. WANG N, Song X, Liu L, Niu L, et al
    Circulating exosomes contain protein biomarkers of metastatic non-small-cell lung cancer.
    Cancer Sci. 2018 Mar 23. doi: 10.1111/cas.13581.
    PubMed     Abstract available

  188. TORIGOE H, Shien K, Takeda T, Yoshioka T, et al
    Therapeutic strategies for afatinib-resistant lung cancer harboring HER2 alterations.
    Cancer Sci. 2018 Mar 13. doi: 10.1111/cas.13571.
    PubMed     Abstract available

    February 2018
  189. XU Y, Ren H, Jiang J, Wang Q, et al
    KIAA0247 inhibits growth, migration, invasion of non-small-cell lung cancer through regulating the Notch pathway.
    Cancer Sci. 2018 Feb 16. doi: 10.1111/cas.13539.
    PubMed     Abstract available

  190. LI W, Zheng G, Xia J, Yang G, et al
    CREPT overexpression is associated with proliferation behaviors and poor prognosis in non-small cell lung cancer.
    Cancer Sci. 2018 Feb 3. doi: 10.1111/cas.13524.
    PubMed     Abstract available

  191. OHARA Y, Chew SH, Shibata T, Okazaki Y, et al
    Phlebotomy as a preventive measure for crocidolite-induced mesothelioma in male rats.
    Cancer Sci. 2018;109:330-339.
    PubMed     Abstract available

  192. LI P, Zhang L, Yu X, Tong R, et al
    Proliferation genes in lung development associated with the prognosis of lung adenocarcinoma but not squamous cell carcinoma.
    Cancer Sci. 2018;109:308-316.
    PubMed     Abstract available

    January 2018
  193. ZHANG Q, Yang J, Bai J, Ren J, et al
    Reverse of non-small cell lung cancer drug resistance induced by cancer associated fibroblasts via a paracrine pathway.
    Cancer Sci. 2018 Jan 30. doi: 10.1111/cas.13520.
    PubMed     Abstract available

  194. KIURA K, Yoh K, Katakami N, Nogami N, et al
    Osimertinib in patients with EGFR T790M advanced non-small cell lung cancer selected using cytology samples.
    Cancer Sci. 2018 Jan 24. doi: 10.1111/cas.13511.
    PubMed     Abstract available

  195. CHARVAT H, Sasazuki S, Shimazu T, Budhathoki S, et al
    Development of a risk prediction model for lung cancer: the Japan Public Health Center-based Prospective Study.
    Cancer Sci. 2018 Jan 18. doi: 10.1111/cas.13509.
    PubMed     Abstract available

    Drug resistance in anaplastic lymphoma kinase-rearranged lung cancer.
    Cancer Sci. 2018 Jan 16. doi: 10.1111/cas.13504.
    PubMed     Abstract available

  197. FAZIO N, Buzzoni R, Delle Fave G, Tesselaar ME, et al
    Everolimus in advanced, progressive, well-differentiated, non-functional neuroendocrine tumors: RADIANT-4 lung subgroup analysis.
    Cancer Sci. 2018;109:174-181.
    PubMed     Abstract available

    December 2017
  198. CHENG HW, Chein RJ, Cheng TJ, Wu PS, et al
    The 2-anilino-4-amino-5-aroylthiazole-type compound AS7128 inhibits lung cancer growth through decreased iASPP and p53 interaction.
    Cancer Sci. 2017 Dec 29. doi: 10.1111/cas.13489.
    PubMed     Abstract available

    November 2017
  199. LIU J, Bian T, Feng J, Qian L, et al
    miR-335 inhibited cell proliferation of lung cancer cells by target Tra2beta.
    Cancer Sci. 2017 Nov 21. doi: 10.1111/cas.13452.
    PubMed     Abstract available

  200. ESAKI N, Ohkawa Y, Hashimoto N, Tsuda Y, et al
    ASCT2 defined by enzyme-mediated activation of radical sources enhances malignancy of GD2-plus small cell lung cancer.
    Cancer Sci. 2017 Nov 19. doi: 10.1111/cas.13448.
    PubMed     Abstract available

  201. OKABE H, Aoki K, Yogosawa S, Saito M, et al
    Downregulation of CD24 suppresses bone metastasis of lung cancer.
    Cancer Sci. 2017 Nov 2. doi: 10.1111/cas.13435.
    PubMed     Abstract available

  202. MAGARA K, Takasawa A, Osanai M, Ota M, et al
    Elevated expression of JAM-A promotes neoplastic properties of lung adenocarcinoma.
    Cancer Sci. 2017;108:2306-2314.
    PubMed     Abstract available

  203. DASSANO A, Pintarelli G, Cotroneo CE, Pettinicchio A, et al
    Complex genetic control of lung tumorigenesis in resistant mice strains.
    Cancer Sci. 2017;108:2281-2286.
    PubMed     Abstract available

    October 2017
  204. KATSURA M, Shoji F, Okamoto T, Shimamatsu S, et al
    Correlation between CXCR4/CXCR7/CXCL12 chemokine axis expression and prognosis in lymph-node-positive lung cancer patients.
    Cancer Sci. 2017 Oct 15. doi: 10.1111/cas.13422.
    PubMed     Abstract available

  205. HUANG LX, Hu CY, Jing L, Wang MC, et al
    microRNA-219-5p inhibits epithelial-mesenchymal transition and metastasis of colorectal cancer by targeting lymphoid enhancer-binding factor 1.
    Cancer Sci. 2017;108:1985-1995.
    PubMed     Abstract available

  206. TAKITA J
    The role of anaplastic lymphoma kinase in pediatric cancers.
    Cancer Sci. 2017;108:1913-1920.
    PubMed     Abstract available

    September 2017
  207. LIU L, Liu J, Shao D, Deng Q, et al
    Comprehensive genomic profiling of lung cancer using a validated panel to explore therapeutic targets in East Asian patients.
    Cancer Sci. 2017 Sep 26. doi: 10.1111/cas.13410.
    PubMed     Abstract available

  208. CHI Y, Jin Q, Liu X, Xu L, et al
    The miR-203 inhibits cell proliferation, invasion, and migration of non-small cell lung cancer by downregulating RGS17.
    Cancer Sci. 2017 Sep 16. doi: 10.1111/cas.13401.
    PubMed     Abstract available

  209. MATSUBARA D, Soda M, Yoshimoto T, Amano Y, et al
    Inactivating mutations and hypermethylation of the NKX2-1/TTF-1 gene in non-terminal respiratory unit-type lung adenocarcinomas.
    Cancer Sci. 2017;108:1888-1896.
    PubMed     Abstract available

    August 2017
  210. KUTKOWSKA J, Strzadala L, Rapak A
    Synergistic activity of sorafenib and betulinic acid against clonogenic activity of non-small cell lung cancer cells.
    Cancer Sci. 2017 Aug 28. doi: 10.1111/cas.13386.
    PubMed     Abstract available

  211. INOUE Y, Matsuura S, Yoshimura K, Iwashita Y, et al
    Characterization of V-set and immunoglobulin domain containing 1 exerting a tumor suppressor function in gastric, lung, and esophageal cancer cells.
    Cancer Sci. 2017;108:1701-1714.
    PubMed     Abstract available

    July 2017
  212. OTSUBO K, Nosaki K, Imamura CK, Ogata H, et al
    Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small cell lung cancer.
    Cancer Sci. 2017 Jul 1. doi: 10.1111/cas.13309.
    PubMed     Abstract available

  213. GRIESING S, Kajino T, Tai MC, Liu Z, et al
    Thyroid transcription factor-1-regulated microRNA-532-5p targets KRAS and MKL2 oncogenes and induces apoptosis in lung adenocarcinoma cells.
    Cancer Sci. 2017;108:1394-1404.
    PubMed     Abstract available

  214. KUNIMASA K, Nagano T, Shimono Y, Dokuni R, et al
    Glucose metabolism-targeted therapy and withaferin A are effective for epidermal growth factor receptor tyrosine kinase inhibitor-induced drug-tolerant persisters.
    Cancer Sci. 2017;108:1368-1377.
    PubMed     Abstract available

    May 2017
  215. TANIGUCHI H, Yamada T, Takeuchi S, Arai S, et al
    The impact of MET inhibition on small-cell lung cancer cells exhibiting aberrant activation of the HGF/MET pathway.
    Cancer Sci. 2017 May 5. doi: 10.1111/cas.13268.
    PubMed     Abstract available

    April 2017
  216. WANG R, Deng X, Yoshioka Y, Vougiouklakis T, et al
    Effects of SMYD2-mediated EML4-ALK methylation on the signaling pathway and growth in non-small cell lung cancer cells.
    Cancer Sci. 2017 Apr 1. doi: 10.1111/cas.13245.
    PubMed     Abstract available

    March 2017
  217. SATO T, Shiba-Ishii A, Kim Y, Dai T, et al
    miR-3941: A novel microRNA that controls IGBP1 expression and is associated with malignant progression of lung adenocarcinoma.
    Cancer Sci. 2017;108:536-542.
    PubMed     Abstract available

  218. KUSUMOTO H, Shintani Y, Kanzaki R, Kawamura T, et al
    Podocalyxin influences malignant potential by controlling epithelial-mesenchymal transition in lung adenocarcinoma.
    Cancer Sci. 2017;108:528-535.
    PubMed     Abstract available

    February 2017
  219. KAMIOKA Y, Takakura K, Sumiyama K, Matsuda M, et al
    Intravital Forster resonance energy transfer imaging reveals osteopontin-mediated polymorphonuclear leukocyte activation by tumor cell emboli.
    Cancer Sci. 2017;108:226-235.
    PubMed     Abstract available

  220. KARASAKI T, Nagayama K, Kuwano H, Nitadori JI, et al
    Prediction and prioritization of neoantigens: integration of RNA sequencing data with whole-exome sequencing.
    Cancer Sci. 2017;108:170-177.
    PubMed     Abstract available

Thank you for your interest in scientific medicine.

AMEDEO Lung Cancer is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.